Moreover, Dai et al. demonstrated that TMZ-resistant GBM cells exhibit increased SCD1 levels, while its downregulation resensitizes GBM cells, revealing SCD1 as a potential target to increase the chemotherapy efficacy in GBM patients (Figure 5C) (Dai et al., 2017). This evidence concerns the gene SCD and glioblastoma.